Innovate Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Innovate Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014136
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innovate Biopharmaceuticals Inc (Innovate) is a clinical stage biotechnology company that develops novel medicines for gastroenterological and orphan disorders. The company’s pipeline product includes INN-329 in phase III for magnetic resonance cholangiopancreatography; and INN-108 in phase II for inflammatory bowel disorders, mild to moderate ulcerative colitis. Its MRCP is a clinical imaging method developed for the visualization of pancreatic ducts, and its secretin stimulated MRCP is a non-invasive, ionizing, radiation-free assessment of the pancreaticobiliary system. The company has patents across the US, Japan and other countries. Innovate is headquartered in Raleigh, North Carolina, the US.

Innovate Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Innovate Biopharma to Acquire Assets Related to RG-1068 from Repligen 10
Venture Financing 11
Innovate Biopharma Raises USD1.4 Million in Venture Financing 11
Innovate Biopharma Raises USD2.7 Million in Venture Financing 12
Merger 13
Monster Digital and Innovate Biopharma to Merge in Reverse Merger Transaction 13
Licensing Agreements 15
Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 15
Innovate Biopharmaceuticals Inc – Key Competitors 16
Innovate Biopharmaceuticals Inc – Key Employees 17
Innovate Biopharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Clinical Trials 19
Feb 21, 2017: Innovate Biopharmaceuticals To Highlight Its Late-Stage Product Pipeline Targeting Celiac Disease And Ulcerative Colitis At The Cowen Healthcare Conference On March 6, 2017 19
Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on INN-108 Phase 2 Trial 20
Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202) 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innovate Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Innovate Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innovate Biopharma to Acquire Assets Related to RG-1068 from Repligen 10
Innovate Biopharma Raises USD1.4 Million in Venture Financing 11
Innovate Biopharma Raises USD2.7 Million in Venture Financing 12
Monster Digital and Innovate Biopharma to Merge in Reverse Merger Transaction 13
Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 15
Innovate Biopharmaceuticals Inc, Key Competitors 16
Innovate Biopharmaceuticals Inc, Key Employees 17

★海外企業調査レポート[Innovate Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Johnny Rockets Group, Inc.:企業の戦略・SWOT・財務情報
    The Johnny Rockets Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Johnny Rockets Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • The Bank of Okinawa, Ltd. (8397):企業の財務・戦略的SWOT分析
    The Bank of Okinawa, Ltd. (8397) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sihuan Pharmaceutical Holdings Group Ltd (460):企業の財務・戦略的SWOT分析
    Summary Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets prescription drugs. The company offers products in the therapeutic areas of cardio-cerebral vascular system, central nervous system, metabolism, oncology and a …
  • Oasis Petroleum Inc (OAS):企業の財務・戦略的SWOT分析
    Oasis Petroleum Inc (OAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Westmoreland Coal Company:企業の戦略・SWOT・財務情報
    Westmoreland Coal Company - Strategy, SWOT and Corporate Finance Report Summary Westmoreland Coal Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野:企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • Commonwealth Bank of Australia:戦略・SWOT・企業財務分析
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • GridPoint, Inc.-エネルギー分野:企業M&A・提携分析
    Summary GridPoint, Inc. (Gridpoint), a subsidiary of Twenty First Century Utilities LLC, is a provider of data-driven energy management systems. The company offers a wide range of energy management hardware including control, equipment-level sub-metering and advanced monitoring devices such as contr …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies. The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. It offers RNAi technology platform GalXCTM, which is a advances …
  • Nexira:企業の戦略・SWOT・財務情報
    Nexira - Strategy, SWOT and Corporate Finance Report Summary Nexira - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • QuadraMed Corp:企業の戦略的SWOT分析
    QuadraMed Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Magnolia Petroleum Plc (MAGP):企業の財務・戦略的SWOT分析
    Summary Magnolia Petroleum Plc (Magnolia Petroleum) is an oil and gas company. The company explores, acquires, and develops oil and natural gas properties. It holds interests in producing properties in two project areas such as Bakken shale in North Dakota and the proven Mississippi Lime, Woodford a …
  • Western Area Power Administration:企業の戦略的SWOT分析
    Western Area Power Administration - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • CareGroup Inc:企業の戦略的SWOT分析
    CareGroup Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Mylan N.V.:企業の戦略・SWOT・財務情報
    Mylan N.V. - Strategy, SWOT and Corporate Finance Report Summary Mylan N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Fugro GeoServices Ltd:企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • PICC Property and Casualty Company Limited:戦略・SWOT・企業財務分析
    PICC Property and Casualty Company Limited - Strategy, SWOT and Corporate Finance Report Summary PICC Property and Casualty Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • EnviroMission Limited (EVM)-エネルギー分野:企業M&A・提携分析
    Summary EnviroMission Limited (Enviro) is a renewable energy company that develops Solar Tower Technology (STT). It owns the license to STT across the world (excluding in China). The STT integrates the use of solar air collector and central updraft tower, to generate solar induced convective flow. I …
  • Qatar Islamic Bank:企業の戦略・SWOT・財務分析
    Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report Summary Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hyperstone GmbH:企業の戦略的SWOT分析
    Hyperstone GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆